System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Sebastian Stintzing is an expert in Oncology at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks Sebastian Stintzing in the top 1% of experts worldwide for Rectal Diseases, Intestinal Neoplasms and Colonic Diseases. Sebastian Stintzing has authored 549 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 9 of them ongoing. SLR score: 2,670 (community average: 125). How the SLR is computed.

LeadR Profile

Sebastian Stintzing Charité - University Medicine Berlin Germany
2 670 ScienceLeadR Reputation 2670

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Charité - University Medicine Berlin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 549

Citations

Citations: 10 141 1st author: 71 Last author: 53 Unique author: 40

Main journals

J Clin Oncol 165
Ann Oncol 55
Eur J Cancer 36
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 24
Cancers (Basel) 14

Best Journals

J Clin Oncol 74
Ann Oncol 23
Lancet Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework.
PMID 42930178 — acetazolamide, hypertension, leukemia, promyelocytic, acute, papilledema, spinal puncture, neoplasms, leukemia, optic nerve, pseudotumor cerebri, therapeutics, punctures, intracranial hypertension, tretinoin		Curr Oncol20260
[Evidenced-based Guideline for Colorectal Cancer].
PMID 42906536 — neoplasms, colorectal neoplasms		Z Gastroenterol20260
Combination of oral fluoropyrimidines and EGFR-directed antibodies in frail patients with metastatic colorectal cancer: a systematic review.
PMID 42902018 — cetuximab, antibodies, neoplasms, antibodies, monoclonal, panitumumab, therapeutics, colorectal neoplasms, capecitabine		J Cancer Res Clin Oncol20260
Microsatellite Instability and Mismatch Repair Subclonality in Human Cancers: Biologic Basis, Diagnostic Pitfalls, and Therapeutic Implications with a Focus on Colorectal Cancer.
PMID 42794922 — bias, dna mismatch repair, microsatellite repeats, neoplasms, therapeutics, colorectal neoplasms, tissues, wounds and injuries, plasma, microsatellite instability, msi-h		Cancers (Basel)20260
Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis.
PMID 42703453 — disease-free survival, progression-free survival, neoplasms, drug therapy, therapeutics, colorectal neoplasms, tissues, mutation, chemotherapy		J Gastrointest Oncol20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 3 8
Phase 1/Phase 2 4
Phase 2 4
N/A 3
Phase 4 1

By status:

Recruiting 10
Completed 5
Unknown 4
Terminated 1

By type:

Interventional 18
Observational 2

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 3
multicentric5to9 1
multicentricup10 7

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 1b 2 study of arfolitixorin as part of 5 fluorouracil based treatment regimens in the first line treatment of metastatic colorectal cancer
2024-516802-43-00 — safety, neoplasms, fluorouracil, therapeutics, colorectal neoplasms		Phase 1/Phase 2Recruiting2025
A personalised approach based on blood and tumor characteristics to guide the post surgical clinical path of patients with operable locoregional colon cancer
2023-509851-15-00 — genomics, blood, neoplasms, colon, precision medicine, therapeutics, colonic neoplasms		Phase 3Recruiting2024
A Clinical Study of Arfolitixorin in Patients With mCRC
NCT06922383 — leucovorin, vascular endothelial growth factor a, safety, cetuximab, digestive system neoplasms, computers, neoplasms, bevacizumab, oxaliplatin, fluorouracil, work, maximum tolerated dose, panitumumab, research, therapeutics, colorectal neoplasms, digestive system, irinotecan		Phase 1/Phase 2Recruiting2025
Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT06787105 — neoplasms, research, therapeutics, colorectal neoplasms		N/ARecruiting2025
The Sagittarius Trial
NCT06490536 — leucovorin, quality of life, genomics, blood, genes, ras, temozolomide, neoplasms, colon, duration of therapy, biopsy, drug therapy, oxaliplatin, fluorouracil, immunotherapy, hiv, nivolumab, precision medicine, panitumumab, therapeutics, ipilimumab, capecitabine, liquid biopsy, irinotecan, trastuzumab, colonic neoplasms, chemotherapy, msi-h		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS